Answers are grounded in this paper and cite their sources.
In patients with aPAP, daily administration of inhaled molgramostim resulted in greater improvements in pulmonary gas transfer and functional health status than placebo, with similar rates of adverse events. (Funded by Savara Pharmaceuticals; IMPALA ClinicalTrials.gov number, NCT02702180.).
No takes yet. Share an insight, caveat, or question.
Trapnell et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: